IPA is Licensed by The National Cancer Institute (NCI)


Mountain View, CA, April 15, 2005 – Ingenuity announced today that the National Cancer Institute (NCI) has licensed access to the IPA software. Under the terms of the agreement all researchers at the NCI will have access to the full functionality of the IPA product.

“Ensuring broad access to IPA for the academic and government research community is a critical goal for Ingenuity in 2005,” stated Jake Leschly, President and CEO of Ingenuity. “We are grateful for the support and guidance that we received from the NCI and other NIH institutes in developing a licensing arrangement that can serve as the model for providing access to IPA for all leading research institutions.”

IPA helps researchers gain biological insight and understanding from their experimental datasets. It is deployed with leading research labs around the world and at 15 of the largest 20 pharmaceutical companies where it is being used to make better and faster decisions in all areas of drug discovery and development, from target identification and validation to biomarkers, predictive toxicology, and patient stratification.

The web-delivered application makes use of the Ingenuity Pathways Knowledge Base, the world’s largest curated database consisting of millions of individually modeled relationships between proteins, genes, complexes, cells, tissues, drugs, and diseases.

About Ingenuity Systems

Ingenuity Systems is helping life science researchers explore and understand biological systems that are foundational to human health and disease. Ingenuity delivers capabilities and expertise to researchers through analysis software, genome-scale computable network databases, and knowledge management services and infrastructure, resulting in increased productivity and faster drugs to market. The company was founded in 1998 and is headquartered in Mountain View, California. www.ingenuity.com.